PainReform drops on late-stage trial data for post-surgical pain management after bunionectomy

seekingalpha

2024-11-20

PainReform (NASDAQ:PRFX) falls about 27% after partial topline data from its contract research organization, Lotus Clinical Research, for the Phase 3 trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
Initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery.
However, data pertaining to the subsequent 24-hour period, which is essential for assessing the primary endpoint of the trial, is currently unclear due to incoherence of the data.
PainReform is collaborating with Lotus to resolve this to complete the analysis of this portion of the data.
Source: Press Release

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2484106831"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484106831\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484106831?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484106831","market":"other","top_or_hot":-1,"title":"PainReform drops on late-stage trial data for post-surgical pain management after bunionectomy","media":"seekingalpha","content":"<html><body><ul> <li><a href=\"https://laohu8.com/S/PRFX\">PainReform</a> (<span>NASDAQ:PRFX</span>) falls about 27% after partial topline data from its contract research organization, Lotus Clinical Research, for the Phase 3 trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.</li> <li>Initial analysis of the topline data indicates that<span> PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery.</span> </li> <li>However, data pertaining to the subsequent 24-hour period, which is essential for assessing the primary endpoint of the trial, is currently unclear due to incoherence of the data.</li> <li>PainReform is collaborating with Lotus to resolve this to complete the analysis of this portion of the data.</li> <li>Source: Press Release </li> </ul> </body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PainReform drops on late-stage trial data for post-surgical pain management after bunionectomy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPainReform drops on late-stage trial data for post-surgical pain management after bunionectomy\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2024-11-20 22:38</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><ul> <li><a href=\"https://laohu8.com/S/PRFX\">PainReform</a> (<span>NASDAQ:PRFX</span>) falls about 27% after partial topline data from its contract research organization, Lotus Clinical Research, for the Phase 3 trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.</li> <li>Initial analysis of the topline data indicates that<span> PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery.</span> </li> <li>However, data pertaining to the subsequent 24-hour period, which is essential for assessing the primary endpoint of the trial, is currently unclear due to incoherence of the data.</li> <li>PainReform is collaborating with Lotus to resolve this to complete the analysis of this portion of the data.</li> <li>Source: Press Release </li> </ul> </body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://seekingalpha.com/news/4311920-painreform-drops-on-late-stage-trial-data-for-post-surgical-pain-management-after-bunionectomy\">seekingalpha</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://seekingalpha.com/news/4311920-painreform-drops-on-late-stage-trial-data-for-post-surgical-pain-management-after-bunionectomy","article_id":"2484106831","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484106831","pubTimestamp":1732113535,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"PainReform  falls about 27% after partial topline data from its contract research organization, Lotus Clinical Research, for the Phase 3 trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery.  However, data pertaining to the subsequent 24-hour period, which is essential for assessing the primary endpoint of the trial, is currently unclear due to incoherence of the data. PainReform is collaborating with Lotus to resolve this to complete the analysis of this portion of the data. Source: Press Release","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PRFX":"PainReform"},"translate_title":"PainReform因拇趾囊肿切除术后疼痛管理的后期试验数据而下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRFX":1},"content_text":"PainReform (NASDAQ:PRFX) falls about 27% after partial topline data from its contract research organization, Lotus Clinical Research, for the Phase 3 trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis of the topline data indicates that PRF-110 demonstrated statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery.  However, data pertaining to the subsequent 24-hour period, which is essential for assessing the primary endpoint of the trial, is currently unclear due to incoherence of the data. PainReform is collaborating with Lotus to resolve this to complete the analysis of this portion of the data. Source: Press Release","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}